BNT162 Vaccine; Oncology; Cancer Research; COVID-19
Disciplines :
Immunology & infectious disease
Author, co-author :
Debie, Yana ; Université de Liège - ULiège > Fundamental and Applied Research for Animals and Health (FARAH) > FARAH: Santé publique vétérinaire ; Multidisciplinary Oncological Centre Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat 655, Edegem, 2650, Belgium, Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp and Antwerp University Hospital, Drie Eikenstraat 655, Edegem, 2650, Belgium
van Dam, Peter A ; Multidisciplinary Oncological Centre Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat 655, Edegem, 2650, Belgium, Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp and Antwerp University Hospital, Drie Eikenstraat 655, Edegem, 2650, Belgium. Electronic address: Peter.vandam@uza.be
Goossens, Maria E ; SD Infectious Diseases in Humans, Service Immune Response, Sciensano, Rue Juliette Wytsmanstraat 14, Brussels, 1050, Belgium
Peeters, Marc; Multidisciplinary Oncological Centre Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat 655, Edegem, 2650, Belgium, Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp and Antwerp University Hospital, Drie Eikenstraat 655, Edegem, 2650, Belgium
Vandamme, Timon ; Multidisciplinary Oncological Centre Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat 655, Edegem, 2650, Belgium, Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp and Antwerp University Hospital, Drie Eikenstraat 655, Edegem, 2650, Belgium
Language :
English
Title :
Boosting capacity of a fourth dose BNT162b2 in cancer patients.
This work was supported by the Belgian Government through Sciensano [ COVID-19_SC004 , COVID-19_SC059 , COVID-19_SC061 , COVID-19_SC104 , COVID-19_SC107 , COVID-19_SC118 ] and Kom op tegen Kanker [ KOTK_UZA/2020/12604/1 ].The authors kindly thank the B-VOICE and Tri-VOICE plus patients for participation, the nursing staff members at the Day Care Unit of the Antwerp University Hospital, the staff members of the Biobank Antwerp and all recruiting physicians. The authors are grateful to Dr. Lise Verbruggen (Multidisciplinary Oncological Centre Antwerp (MOCA), Antwerp University Hospital) and Dr. Greetje Vanhoutte (Multidisciplinary Oncological Centre Antwerp (MOCA), Dr. Laure-Anne Teuwen, MD (Multidisciplinary Oncological Centre Antwerp (MOCA), Antwerp University Hospital) and Dr. Pieter Pannus (SD Infectious Diseases in Humans, Service Immune response, Sciensano) for logistic support and critical revision of the manuscript and The authors are thankful to the clinical biology study team for serological analysis. In addition, the authors thank the B-VOICE and TRI-VOICE plus study teams for patient inclusion and sample collection. This work was supported by the Belgian Government through Sciensano [COVID-19_SC004, COVID-19_SC059, COVID-19_SC061, COVID-19_SC104, COVID-19_SC107, COVID-19_SC118] and Kom op tegen Kanker [KOTK_UZA/2020/12604/1].
Peeters, M., Verbruggen, L., Teuwen, L., et al. Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment. ESMO Open, 6(5), 2021, 100274.
Debie, Y, Vandamme, T, Goossens, ME, van Dam, PA, Peeters, M, Antibody titers before and after a third dose of the SARS-CoV-2 BNT162b2 vaccine in cancer patients. Eur J Cancer 163 (2022), 177–179.
Barrière, J., Carles, M., Audigier-Valette, C., et al. Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: should humoral responses be monitored? A position article. Eur J Cancer 162 (2022), 182–193.
Ferdinands, J.M., Rao, S., Dixon, B.E., et al. Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance - VISION Network, 10 states, August 2021-January 2022. MMWR Morb Mortal Wkly Rep 71:7 (2022), 255–263.
Rastawicki, W., Juszczyk, G., Gierczyński, R., Zasada, A.A., Comparison of anti-SARS-CoV-2 IgG and IgA antibody responses post complete vaccination, 7 months later and after 3rd dose of the BNT162b2 vaccine in healthy adults. J Clin Virol: Off Publ Pan Am Soc Clin Virol, 152, 2022, 105193.
Aikawa, N.E., Kupa, L.V.K., Silva, C.A., et al. Strong response after 4th dose of mRNA COVID-19 vaccine in autoimmune rheumatic diseases patients with poor response to inactivated vaccine. Rheumatology (Oxford, England), 2022.
Grewal, R., Kitchen, S.A., Nguyen, L., et al. Effectiveness of a fourth dose of Covid-19 mRNA vaccine against the omicron variant among long term care residents in Ontario, Canada: test negative design study. BMJ (Clinical Research ed), 378, 2022, e071502.
Munro, A.P.S., Feng, S., Janani, L., et al. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. Lancet Infect Dis 22:8 (2022), 1131–1141.
Magen, O., Waxman, J.G., Makov-Assif, M., et al. Fourth dose of BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med 386:17 (2022), 1603–1614.
Garassino, M.C., Vyas, M., de Vries, E.G.E., et al. The ESMO Call to Action on COVID-19 vaccinations and patients with cancer: vaccinate. Monitor. Educate. Ann Oncol 32:5 (2021), 579–581.
